Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib Combined with Chemotherapy in Osteosarcoma
NCT05926492Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2024
- Primary completion
- Jul 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in osteosarcoma (OS), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Jan 2024; status: recruiting.
02
Drugs
surufatinib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT05926492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05926492.